You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 127 No. 7, July 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Ophthalmology, Other
 •Patient-Physician Relationship/ Care
 •Treatment Adherence
 •Drug Therapy
 •Adherence
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Medication Costs Matter

Alan R. Morse, PhD

Arch Ophthalmol. 2009;127(7):929-931.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drugs don't work in patients who don't take them.
C. Everett Koop

Health care cost escalation has been dramatic. In 1960, the first year such data were available, health expenditures were estimated to be $526 million dollars, or 5.1% of the US gross domestic product and $148 per capita, growing to approximately $2.2 trillion, almost $7500 per capita, by 2007. By 2016, the Centers for Medicare and Medicaid Services estimates that health care spending in the United States will be more than $4.1 trillion, equal to about 19.6% of the gross domestic product and $12 782 per capita. Spending levels for prescription drugs have increased even more rapidly than overall health care costs, growing from $24 billion, which was 5.1% of overall health care costs in 1986, to $217 billion, more than 10.3% of health care costs in 2006.1 The National Association of Chain Drug Stores . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Modalities to Decrease Stromal Herpes Simplex Keratitis Reactivation Rates
John D. Sheppard, Michael L. Wertheimer, and Stephen V. Scoper
Arch Ophthalmol. 2009;127(7):852-856.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.